Covid-19 and Porphyria

The American Porphyria Foundation will continue to share updates regarding COVID-19 in collaboration with the expert physicians of the Porphyrias Consortium and our pharmaceutical partners.

In general, patients with porphyrias, unless they also have heart, lung, kidney, or liver disease and/or are receiving immunosuppressive therapy or chemotherapy for non-porphyric diseases, are NOT at increased risk for contracting Covid-19 infection, nor at increased risk for adverse outcomes if they do.

The APF remains open and available to support your needs and questions during the COVID-19 pandemic. Please contact 866-APF-3635 or

Coronavirus (Covid-19) Statement
Emergency Department Guidelines
Statements on availability of treatment
Safety of treatments in clinical trial
Support Programs


Porphyrias Consortiums expert, Dr. Bruce Wang, University of California San Francisco (UCSF), shares a video message with the porphyria community regarding COVID-19. Dr. Wang reviews the effects of the virus on patients with porphyria, and also advises on preventative care measures.